Building on clinical trial and laboratory research insights from the past decade, the ITN has focused and deliberate strategies to achieving tolerance in each disease area. The research supported by the ITN has unlocked new therapeutic approaches and discovered new biomarkers that promise to change the way physicians treat patients. Explore ITN clinical trials below by using a search term or by sorting the specific trial categories. If you have questions or want more information about ITN clinical trials, contact us.
Patrick Nachman, MD , University of Minnesota
Ignacio Sanz, MD , Emory University
REBOOT will test whether a combination of, belimumab and rituximab, is safe and if this combination is more effective at blocking the immune attack on the kidney of patients with Primary Membranous Neuropathy (MN).
Jeffrey Cohen, MD, Cleveland Clinic
George Georges, MD, Fred Hutchinson Cancer Research Center
Paolo Muraro, MD, PhD, Imperial College London
BEAT-MS is a clinical trial comparing chemotherapy followed by autologous hematopoietic stem cell transplant (AHSCT) – a type of bone marrow transplantation – to the most effective medicines regularly used to treat relapsing MS.
Allan Kirk, MD, PhD, Duke University School of Medicine
TEACH is a clinical trial investigating whether cells from the kidney donor's bone marrow, called mesenchymal stromal cells (MSCs) will allow kidney transplant recipients to stop immunosuppressive medications.
Hugh Sampson, MD , Icahn School of Medicine at Mount Sinai , New York
Jose Clemente, PhD , Icahn Institute for Genomics and Multiscale Biology , New York
ACTIVATE is a clinical trial investigating the impact of the infant microbiome on allergy development.
James Markman, MD, PhD , Massachusetts General Hospital , Boston, MA;
Sandy Feng, MD, PhD , University of California San Francisco , San Francisco, CA
LITTMUS is a clinical research study testing a new approach to achieve transplant tolerance using the liver transplant recipient’s own T regulatory cells (Tregs).
Gideon Lack, Evelina Childrens Hospital, London, UK
LEAP Trio is a follow-up to the LEAP study of early peanut consumption. LEAP Trio will investigate the durability of tolerance to peanut allergen in LEAP participants at age 12, development of peanut allergy in younger siblings of LEAP participants, and parental characteristics that may impact development of food allergy.
David Fox, MD , University of Michigan , Ann Arbor, MI
Dinesh Khanna, MD , University of Michigan , Ann Arbor, MI
BRAVOS is a clinical trial evaluating Brentuximab Vendotin treatment for Diffuse Cutaneous Systemic Sclerosis.
Linda DiMeglio, MD, MPH, Indiana University and Riley Hospital for Children, Indianapolis, IN
T1DES is a clinical study for people with type 1 diabetes who were previously enrolled in an ITN clinical study.
James Markmann, MD, PhD, Massachusettes General Hospital, Boston, MA
OPTIMAL is a clinical trial that will be investigating immunosuppression withdrawal in liver transplant recipients.
Betty Diamond, MD, Feinstein Institute, Manhasset, NY
David Wofsy, MD, University of California San Francisco, San Francisco, CA
The objective of the CALIBRATE study is to determine if treating lupus nephritis with a combination of rituximab (Rituxan®) and cyclophosphamide (Cytoxan®), or a combination of rituximab and cyclophosphamide followed by treatment with belimumab (Benlysta®) is safe and if this drug combination can block the immune system attacks on the kidney.
Carla Greenbaum, MD, Benaroya Research Institute, Seattle, WA
Jane Buckner, MD, Benaroya Research Institute, Seattle, WA
EXTEND is a clinical research study that will test whether a therapy called tocilizumab (Actemra®) can stop the immune system from attacking the remaining beta cells and possibly extend the ability to naturally produce insulin in individuals recently diagnosed with type 1 diabetes.
James Krueger, MD, PhD, Rockefeller University, New York, NY
PAUSE is a clinical trial testing the effectiveness of ustekinumab (STELARA ®) followed by an investigational drug, abatacept, for the treatment of psoriasis. The main goal of the study is to determine the efficacy of abatacept to induce prolonged remission.
Samia Khoury, Harvard Medical School, Boston, MA
ACCLAIM is a Phase II clinical research trial of the safety and efficacy of abatacept in adults with relapsing-remitting multiple sclerosis (RRMS). The study is testing whether abatacept works differently from most other MS treatments, as it is more specific in the immune cells that it targets.
Sindhu Chandran, MD, University of California, San Francisco, San Francisco, CA
ALLTOL is an observational clinical study to learn more about tolerance in organ transplantation.
Stephen Durham, MD, Imperial College London, London, UK
Piyush Patal, MD, Inflamax Research, Ontario, Canada
The goal of the CAT EEC study is to directly compare allergic responses to cat by environmental exposure chamber vs. nasal allergen challenge to better understand and employ these methods as allergy evaluation tools in clinical trials.
Jonathan Corren, MD, University of California, Los Angeles, Los Angeles, CA
CATNIP is a clinical research trial, which will test whether a novel therapeutic approach, cat immunotherapy combined with an investigational new drug called MEDI9929/AMG 157 (an anti-TSLP antibody being co-developed by Amgen and Medimmune) can lead to lasting tolerance to cat allergen. This study will implement the concept referred to as “allergen-plus,” which aims to enhance the disease-modifying mechanisms of allergen-specific immunotherapy by combining it with other anti-inflammatory or immune-modulating agents.
Lode Swinnen, MD, Johns Hopkins Hospital, Baltimore, MD
This trial is a phase II, single arm, open-label, single center study to assess the ability of a specialized pre-transplant conditioning regimen, bone marrow transplantation and high dose post-transplant cyclophosphamide to induce tolerance and enable long-term discontinuation of immunosuppression in six kidney transplant recipients.
Wesley Burks, MD, UNC Chapel Hill, Chapel Hill, NC
IMPACT is a clinical research study testing whether daily oral exposure to a peanut product can modify peanut allergy in young children.
Daniel C. Brennan, MD, Washington University, St. Louis, MO
This study is for participants who have received up to three islet cell infusions as a previous participant in the ITN005CT study. Study participants will receive a maintenance immunosuppressive treatment regimen consisting of a combination of orally administered drugs (tacrolimus (Prograf®), sirolimus (Rapamune®), mycophenolate mofetil (MMF, Cellcept®), and/or mycophenolic acid (MPA, Myfortic®).) This protocol provides a way to supply these immunosuppressive medications to subjects whose islets continue to function and make C-peptide.
Gideon Lack, MD, Evelina Children's Hospital, London, UK
This is a follow-on study to the ITN’s LEAP trial to evaluate the persistence of tolerance to peanut, and whether continued consumption of peanuts throughout life is required in order to be able to safely eat peanuts without reacting.